Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?

IF 1.9 Q2 ORTHOPEDICS Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders Pub Date : 2021-03-16 eCollection Date: 2021-01-01 DOI:10.1177/11795441211002492
Christopher Vannabouathong, Meng Zhu, Yaping Chang, Mohit Bhandari
{"title":"Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?","authors":"Christopher Vannabouathong,&nbsp;Meng Zhu,&nbsp;Yaping Chang,&nbsp;Mohit Bhandari","doi":"10.1177/11795441211002492","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic knee pain is a common musculoskeletal condition, which usually leads to decreased quality of life and a substantial financial burden. Various non-surgical treatments have been developed to relieve pain, restore function and delay surgical intervention. Research on the benefits of medical cannabis (MC) is emerging supporting its use for chronic pain conditions. The purpose of this study was to evaluate the cost-effectiveness of MC compared to current non-surgical therapies for chronic knee pain conditions.</p><p><strong>Methods: </strong>We conducted a cost-utility analysis from a Canadian, single payer perspective and compared various MC therapies (oils, soft gels and dried flowers at different daily doses) to bracing, glucosamine, pharmaceutical-grade chondroitin oral non-steroidal anti-inflammatory drugs (NSAIDs), and opioids. We estimated the quality-adjusted life years (QALYs) gained with each treatment over 1 year and calculated incremental cost-utility ratios (ICURs) using both the mean and median estimates for costs and utilities gained across the range of reported values. The final ICURs were compared to willingness-to-pay (WTP) thresholds of $66 714, $133 428 and $200 141 Canadian dollars (CAD) per QALY gained.</p><p><strong>Results: </strong>Regardless of the estimates used (mean or median), both MC oils and soft gels at both the minimal and maximal recommended daily doses were cost-effective compared to all current knee pain therapies at the lowest WTP threshold. Dried flowers were only cost-effective up to a certain dosage (0.75 and 1 g/day based on mean and median estimates, respectively), but all dosages were cost-effective when the WTP was increased to $133 428/QALY gained.</p><p><strong>Conclusion: </strong>Our study showed that MC may be a cost-effective strategy in the management of chronic knee pain; however, the evidence on the medical use of cannabis is limited and predominantly low-quality. Additional trials on MC are definitely needed, specifically in patients with chronic knee pain.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"14 ","pages":"11795441211002492"},"PeriodicalIF":1.9000,"publicationDate":"2021-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11795441211002492","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795441211002492","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic knee pain is a common musculoskeletal condition, which usually leads to decreased quality of life and a substantial financial burden. Various non-surgical treatments have been developed to relieve pain, restore function and delay surgical intervention. Research on the benefits of medical cannabis (MC) is emerging supporting its use for chronic pain conditions. The purpose of this study was to evaluate the cost-effectiveness of MC compared to current non-surgical therapies for chronic knee pain conditions.

Methods: We conducted a cost-utility analysis from a Canadian, single payer perspective and compared various MC therapies (oils, soft gels and dried flowers at different daily doses) to bracing, glucosamine, pharmaceutical-grade chondroitin oral non-steroidal anti-inflammatory drugs (NSAIDs), and opioids. We estimated the quality-adjusted life years (QALYs) gained with each treatment over 1 year and calculated incremental cost-utility ratios (ICURs) using both the mean and median estimates for costs and utilities gained across the range of reported values. The final ICURs were compared to willingness-to-pay (WTP) thresholds of $66 714, $133 428 and $200 141 Canadian dollars (CAD) per QALY gained.

Results: Regardless of the estimates used (mean or median), both MC oils and soft gels at both the minimal and maximal recommended daily doses were cost-effective compared to all current knee pain therapies at the lowest WTP threshold. Dried flowers were only cost-effective up to a certain dosage (0.75 and 1 g/day based on mean and median estimates, respectively), but all dosages were cost-effective when the WTP was increased to $133 428/QALY gained.

Conclusion: Our study showed that MC may be a cost-effective strategy in the management of chronic knee pain; however, the evidence on the medical use of cannabis is limited and predominantly low-quality. Additional trials on MC are definitely needed, specifically in patients with chronic knee pain.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医用大麻疗法在慢性膝关节疼痛的非手术治疗中是否具有成本效益?
慢性膝关节疼痛是一种常见的肌肉骨骼疾病,通常会导致生活质量下降和巨大的经济负担。各种非手术治疗已经发展到减轻疼痛,恢复功能和延迟手术干预。关于医用大麻(MC)益处的研究正在兴起,支持将其用于慢性疼痛病症。本研究的目的是评估MC与目前非手术治疗慢性膝关节疼痛的成本-效果。方法:我们从加拿大单一付款人的角度进行了成本效用分析,并比较了各种MC疗法(不同日剂量的油、软凝胶和干花)与支具、氨基葡萄糖、药用级软骨素口服非甾体抗炎药(NSAIDs)和阿片类药物。我们估计了1年内每次治疗获得的质量调整生命年(QALYs),并使用报告值范围内获得的成本和效用的平均值和中位数估计计算了增量成本效用比(ICURs)。将最终的icur与每个获得的QALY的支付意愿(WTP)阈值进行比较,分别为66 714美元、133 428美元和200 141美元。结果:无论使用的估计值(平均值或中位数)如何,与目前所有最低WTP阈值的膝关节疼痛治疗方法相比,最小和最大推荐日剂量的MC油和软凝胶都具有成本效益。干花仅在一定剂量下具有成本效益(分别根据平均值和中位数估计分别为0.75和1 g/天),但当WTP增加到133 428美元/QALY时,所有剂量都具有成本效益。结论:我们的研究表明,MC可能是治疗慢性膝关节疼痛的一种经济有效的策略;然而,关于大麻医疗用途的证据有限,而且主要是低质量的。对MC的进一步试验肯定是需要的,特别是对慢性膝关节疼痛患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
14
审稿时长
8 weeks
期刊最新文献
Is CRPS-1 a Chronic Disabling Disease? A Long-term, Real-Life Study on Patients Treated With Neridronate. The Impact of Tobacco Smoking on Systemic Sclerosis, Idiopathic Inflammatory Myositis, and Systemic Lupus Erythematosus. Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus. Good Short- and Mid-term Outcome After Cross-Linked Hyaluronic Acid Infiltration for Hallux Rigidus: A Case Report. Idiopathic Granulomatous Mastitis, Erythema Nodosum, and Polyarthritis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1